Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia

NCT00435279 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT00435279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00435279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
July 31, 2009
Enrollment
678 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia, major depressive disorder